Bibliography
- Brown CJ, Lain S, Verma CS, Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009;9(12):862-73
- Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6(12):909-23
- Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 2009;7(1):1-11
- Weber L. Patented inhibitors of p53-Mdm2 interaction (2006 – 2008). Expert Opin Ther Pat 2010;20(2):179-91
- Macchiarulo A, Pellicciari R. MDM2/MDMX inhibitor peptide: WO2008106507. Expert Opin Ther Pat 2009;19(5):721-6
- Kallen J, Goepfert A, Blechschmidt A, Crystal structures of human MdmX (HdmX) in complex with p53 peptide analogues reveal surprising conformational changes. J Biol Chem 2009;284(13):8812-21
- Grasslin A, Amoreira C, Baldridge KK, Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2. Chembiochem 2009;10(8):1360-8
- Fasan R, Dias RL, Moehle K, Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Angew Chem Int Ed Engl 2004;43(16):2109-12
- Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 2007;67(18):8810-17
- Weissman AM, Yang Y, Kitagaki J, Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer. Ernst Schering Found Symp Proc 2008;1:171-90
- Lai Z, Yang T, Kim YB, Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 2002;99(23):14734-9
- Wang WG, Ho WC, Dicker DT, Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther 2005;4(8):893-8
- Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them. WO2004043955; 2004
- Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors. WO2005007621; 2005
- Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors. WO2006074262; 2006
- Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors. US2006160869; 2006
- Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors. US20050009871; 2005
- Murray MF, Jurewicz AJ, Martin JD, A high-throughput screen measuring ubiquitination of p53 by human mdm2. J Biomol Screen 2007;12(8):1050-8
- Yang Y, Ludwig RL, Jensen JP, Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005;7(6):547-59
- Wilson JM, Henderson G, Black F, Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells. Bioorg Med Chem 2007;15(1):77-86
- Kitagaki J, Agama KK, Pommier Y, Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol Cancer Ther 2008;7(8):2445-54
- Beljanski M, Beljanski MS. Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs. Oncology 1986;43(3):198-203
- Sasiela CA, Stewart DH, Kitagaki J, Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J Biomol Screen 2008;13(3):229-37
- Clement JA, Kitagaki J, Yang Y, Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53. Bioorgan Med Chem 2008;16(23):10022-28
- Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009;78:399-434
- MOE, Molecular Operating Environment, Chemical Computing Group, Inc. ver. 2009-10, Montreal, Quebec, Canada